We take a partnership approach to developing real-world solutions for health issues
The School is pivotal to a range of exciting strategic initiatives:
UCLPartners is an academic health science partnership with over 40 higher education and NHS members. It facilitates the improvement of healthcare through a range of clinical and academic designated roles, as an Academic Health Science Centre (AHSC), Academic Health Science Network (AHSN), an Education Lead Provider and aligned with the NIHR Collaboration for Leadership in Applied Health Research and Care and the NIHR Clinical Research Network North Thames.
UCLPartners is the only academic health science partnership in the country to align all of these NHS and Department of Health designated roles under one umbrella to translate innovation into health and wealth benefits for patients.
The work of the UCLPartners AHSC is facilitated by the Office of the Vice Provost (Health), providing coordination and project management support for the six programmes and three cross-cutting domains:
3 Cross-cutting domains:
The Francis Crick Institute will be an inter-disciplinary medical research institute due to open in 2015 next to St Pancras railway station near UCL's Bloomsbury campus. Its work will help understand why disease develops and find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease and stroke, infections, and neurodegenerative diseases.
It is a consortium of six of the UK's most successful scientific and academic organisations - the Medical Research Council, Cancer Research UK, the Wellcome Trust, UCL, Imperial College London and King's College London.
For more information about UCL's engagement with the Francis Crick Institute please visit the UCL@Crick website.
CASMI is the Centre for the Advancement of Sustainable Medical Innovation, a partnership between UCL and the University of Oxford, created to develop new models for medical innovation. The centre aims to address the issues that have led to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.
Building on a history of increasing collaboration between UCLPartners, King’s Health Partners, Imperial College Academic Health Science Centre, Oxford and Cambridge, MedCity has been established in partnership with the Greater London Authority (GLA) to provide a vehicle to realise that ambition, ensuring London and the Greater South East become the a global hub for the development of novel therapeutics, devices and diagnostics to address medical need.
For details of UCL's engagement with MedCity visit the UCL@MedCity website.
UCL is a founder member of the Global Medical Excellence Cluster (GMEC) which brings together key players in biomedical research and patient care in six UK major centres (UCL, Cambridge, Imperial, King's College London, Oxford and Queen Mary, University of London) to strengthen the UK research landscape and to take on challenging problems in healthcare and drug discovery.
UCL staff can access additional partnership resources (slides, key contacts, images and logos) via the SLMS intranet.